LTBP2

Across TCGA pan-cancer cohorts, LTBP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LTBP2 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LTBP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LTBP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where LTBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	46	view →
GBM	DFS	Tertile	All	0.245	0.532	<.001	16	view →
PDAC	DFS	Median	All	0.829	0.694	.005	16	view →
LSCC	DFS	Quartile	II,III,IV	0.625	0.938	.036	5	view →
HNSC	OS	Tertile	IV	0.693	0.867	.044	2	view →
LUAD	DFS	Quartile	All	0.748	0.454	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LTBP2–CCRCC (DFS)

Open the CCRCC breakdown →